Patents by Inventor Bennett C. Borer

Bennett C. Borer has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Crystalline forms of Mnk inhibitors
    Patent number: 11952375
    Abstract: The present invention provides crystalline solids of 6?-((6-aminopyrimidin-4-yl)amino)-8?-methyl-2?H-spiro[cyclohexane-1,3?-imidazo[1,5-a]pyridine]-1?,5?-dione: The crystalline compounds of the present application are inhibitors of Mnk and finds utility in any number of therapeutic applications, including but not limited to treatment of inflammation and various cancers.
    Type: Grant
    Filed: September 24, 2021
    Date of Patent: April 9, 2024
    Assignee: eFFECTOR Therapeutics Inc.
    Inventors: Siegfried H. Reich, Paul A. Sprengeler, Stephen E. Webber, Alan X. Xiang, Justin T. Ernst, Bennett C. Borer, Samuel Sperry, Jo Ann Z. Wilson
  • CRYSTALLINE FORMS OF MNK INHIBITORS
    Publication number: 20220119387
    Abstract: The present invention provides crystalline solids of 6?-((6-aminopyrimidin-4-yl)amino)-8?-methyl-2?H-spiro[cyclohexane-1,3?-imidazo[1,5-a]pyridine]-1?,5?-dione: The crystalline compounds of the present application are inhibitors of Mnk and finds utility in any number of therapeutic applications, including but not limited to treatment of inflammation and various cancers.
    Type: Application
    Filed: September 24, 2021
    Publication date: April 21, 2022
    Inventors: Siegfried H. REICH, Paul A. Sprengeler, Stephen E. Webber, Alan X. Xiang, Justin T. Ernst, Bennett C. Borer, Samuel Sperry, Jo Ann Z. Wilson
  • Crystalline forms of MNK inhibitors
    Patent number: 11130757
    Abstract: The present invention provides crystalline solids of 6?-((6-aminopyrimidin-4-yl)amino)-8?-methyl-2?H-spiro[cyclohexane-1,3?-imidazo[1,5-a]pyridine]-1?,5?-dione: The crystalline compounds of the present application are inhibitors of Mnk and finds utility in any number of therapeutic applications, including but not limited to treatment of inflammation and various cancers.
    Type: Grant
    Filed: October 23, 2019
    Date of Patent: September 28, 2021
    Assignee: eFFECTOR Therapeutics Inc.
    Inventors: Siegfried H. Reich, Paul A. Sprengeler, Stephen E. Webber, Alan X. Xiang, Justin T. Ernst, Bennett C. Borer, Samuel Sperry, Jo Ann Z. Wilson
  • CRYSTALLINE FORMS OF MNK INHIBITORS
    Publication number: 20200131179
    Abstract: The present invention provides crystalline solids of 6?-((6-aminopyrimidin-4-yl)amino)-8?-methyl-2?H-spiro[cyclohexane-1,3?-imidazo[1,5-a]pyridine]-1?,5?-dione: The crystalline compounds of the present application are inhibitors of Mnk and finds utility in any number of therapeutic applications, including but not limited to treatment of inflammation and various cancers.
    Type: Application
    Filed: October 23, 2019
    Publication date: April 30, 2020
    Inventors: Siegfried H. Reich, Paul A. Sprengeler, Stephen E. Webber, Alan X. Xiang, Justin T. Emst, Bennett C. Borer, Samuel Sperry, Jo Ann Z. Wilson
  • PROCESS OF PRODUCING PHOSPHINOTHRICIN EMPLOYING NITRILASES
    Publication number: 20170247399
    Abstract: The present invention generally relates to processes for the enzymatic production of a phosphinothricin product or precursor thereof from a nitrile-containing substrate.
    Type: Application
    Filed: May 15, 2017
    Publication date: August 31, 2017
    Applicant: Strategic Enzyme Applications, Inc.
    Inventors: Kim F. Albizati, Spiros Kambourakis, Alan Grubbs, Bennett C. Borer
  • Process of producing phosphinothricin employing nitrilases
    Patent number: 9683001
    Abstract: The present invention generally relates to processes for the enzymatic production of a phosphinothricin product or precursor thereof from a nitrile-containing substrate.
    Type: Grant
    Filed: March 4, 2015
    Date of Patent: June 20, 2017
    Assignee: Stragegic Enzyme Applications, Inc.
    Inventors: Kim F. Albizati, Spiros Kambourakis, Alan Grubbs, Bennett C. Borer
  • Process of Producing Phosphinothricin Employing Nitrilases
    Publication number: 20150239917
    Abstract: The present invention generally relates to processes for the enzymatic production of a phosphinothricin product or precursor thereof from a nitrile-containing substrate.
    Type: Application
    Filed: March 4, 2015
    Publication date: August 27, 2015
    Applicant: STRATEGIC ENZYME APPLICATIONS, INC.
    Inventors: Kim F. Albizati, Spiros Kambourakis, Alan Grubbs, Bennett C. Borer
  • Process of producing phosphinothricin employing nitrilases
    Patent number: 8981142
    Abstract: The present invention generally relates to processes for the enzymatic production of a phosphinothricin product or precursor thereof from a nitrile-containing substrate.
    Type: Grant
    Filed: April 14, 2010
    Date of Patent: March 17, 2015
    Assignee: Strategic Enzyme Applications, Inc.
    Inventors: Kim F. Albizati, Spiros Kambourakis, Alan Grubbs, Bennett C. Borer
  • PROCESS OF PRODUCING PHOSPHINOTHRICIN EMPLOYING NITRILASES
    Publication number: 20130204031
    Abstract: The present invention generally relates to processes for the enzymatic production of a phosphinothricin product or precursor thereof from a nitrile-containing substrate.
    Type: Application
    Filed: April 14, 2010
    Publication date: August 8, 2013
    Applicant: STRATEGIC ENZYME APPLICATIONS, INC.
    Inventors: Kim F. Albizati, Spiros Kambourakis, Alan Grubbs, Bennett C. Borer
  • Methods for the preparation of intermediates in the synthesis of HIV-protease inhibitors
    Publication number: 20030023092
    Abstract: Methods for the preparation of chemical intermediates in the synthesis of HIV-protease inhibitors related to and including nelfinavir mesylate are disclosed. The method of this invention comprises converting tetrohydran derivatives into oxazolines to provide key reaction intermediates for the preparation of nelfinavir. Also disclosed is a method for the preparation of a chiral amino alcohol from an epoxy-tetrahydrofuran.
    Type: Application
    Filed: August 26, 2002
    Publication date: January 30, 2003
    Inventors: Bennett C. Borer, Scott E. Zook, Juliette K. Busse
  • Methods for the preparation of intermediates in the synthesis of HIV-protease inhibitors
    Patent number: 6472534
    Abstract: Methods for the preparation of chemical intermediates in the synthesis of HIV-protease inhibitors related to and including nelfinavir mesylate are disclosed. The method of this invention comprises converting tetrohydran derivatives into oxazolines to provide key reaction intermediates for the preparation of nelfinavir. Also disclosed is a method for the preparation of a chiral amino alcohol from an epoxy-tetrahydrofuran.
    Type: Grant
    Filed: November 7, 2001
    Date of Patent: October 29, 2002
    Assignee: Agouron Pharmaceuticals, Inc.
    Inventors: Bennett C. Borer, Scott E. Zook, Juliette K. Busse
  • Methods of making HIV-protease inhibitors and intermediates for making HIV-protease inhibitors
    Patent number: 6465661
    Abstract: HIV protease inhibitors inhibit or block the biological activity of the HIV protease enzyme, causing the replication of the HIV virus to terminate. These compounds can be prepared by the novel methods of the present invention using the novel inventive intermediates.
    Type: Grant
    Filed: March 21, 2002
    Date of Patent: October 15, 2002
    Assignee: Agouron Pharmaceuticals, Inc.
    Inventors: Srinivasan Babu, Bennett C. Borer, Travis P. Remarchuk, Robert J. Szendroi, Kathleen R. Whitten, Juliette K. Busse, Kim F. Albizati
  • Methods for the preparation of intermediates in the synthesis of HIV-protease inhibitors
    Patent number: 6403799
    Abstract: Methods for the preparation of chemical intermediates in the synthesis of HIV-protease inhibitors related to and including nelfinavir mesylate are disclosed. The method of this invention comprises converting tetrohydran derivatives into oxazolines to provide key reaction intermediates for the preparation of nelfinavir. Also disclosed is a method for the preparation of a chiral amino alcohol from an epoxy-tetrahydrofuran.
    Type: Grant
    Filed: October 17, 2000
    Date of Patent: June 11, 2002
    Assignee: Agouron Pharmaceuticals, Inc.
    Inventors: Bennett C. Borer, Scott E. Zook, Juliette K. Busse
  • Methods of making HIV-protease inhibitors and intermediates for making HIV-protease inhibitors
    Patent number: 6392067
    Abstract: HIV protease inhibitors inhibit or block the biological activity of the HIV protease enzyme, causing the replication of the HIV virus to terminate. These compounds can be prepared by the novel methods of the present invention using the novel inventive intermediates.
    Type: Grant
    Filed: May 21, 2001
    Date of Patent: May 21, 2002
    Assignees: Agouron Pharmaceuticals, Inc., Japan Tobacco Inc.
    Inventors: Srinivasan Babu, Bennett C. Borer, Travis P. Remarchuk, Robert J. Szendroi, Kathleen R. Whitten, Juliette K. Busse, Kim F. Albizati
  • Methods for the preparation of intermediates in the synthesis of HIV-protease inhibitors
    Publication number: 20020038033
    Abstract: Methods for the preparation of chemical intermediates in the synthesis of HIV-protease inhibitors related to and including nelfinavir mesylate are disclosed. The method of this invention comprises converting tetrohydran derivatives into oxazolines to provide key reaction intermediates for the preparation of nelfinavir. Also disclosed is a method for the preparation of a chiral amino alcohol from an epoxy-tetrahydrofuran.
    Type: Application
    Filed: November 7, 2001
    Publication date: March 28, 2002
    Inventors: Bennett C. Borer, Scott E. Zook, Juliette K. Busse
  • Methods of making HIV-protease inhibitors and intermediates for making HIV-protease inhibitors
    Patent number: 6316625
    Abstract: HIV protease inhibitors inhibit or block the biological activity of the HIV protease enzyme, causing the replication of the HIV virus to terminate. These compounds can be prepared by the novel methods of the present invention using the novel inventive intermediates.
    Type: Grant
    Filed: July 21, 2000
    Date of Patent: November 13, 2001
    Assignees: Agouron Pharmaceuticals, Inc., Japan Tobacco Inc.
    Inventors: Srinivasan Babu, Bennett C. Borer, Travis P. Remarchuk, Robert J. Szendroi, Kathleen R. Whitten, Juliette K. Busse, Kim F. Albizati
  • Methods of making HIV-protease inhibitors and intermediates for making HIV-protease inhibitors
    Patent number: 6117999
    Abstract: HIV protease inhibitors inhibit or block the biological activity of the HIV protease enzyme, causing the replication of the HIV virus to terminate. These compounds can be prepared by the novel methods of the present invention using the novel inventive intermediates.
    Type: Grant
    Filed: February 19, 1999
    Date of Patent: September 12, 2000
    Assignees: Agouron Phramaceuticals, Inc., Japan Tobacco, Inc.
    Inventors: Srinivasan Babu, Bennett C. Borer, Travis P. Remarchuk, Robert J. Szendroi, Kathleen R. Whitten, Juliette K. Busse, Kim F. Albizati
  • Intermediates for making HIV-protease inhibitors
    Patent number: 6084107
    Abstract: HIV protease inhibitors inhibit or block the biological activity of the HIV protease enzyme, causing the replication of the HIV virus to terminate. These compounds can be prepared by the novel methods of the present invention using the novel inventive intermediates.
    Type: Grant
    Filed: September 5, 1997
    Date of Patent: July 4, 2000
    Assignee: Agouron Pharmaceuticals, Inc.
    Inventors: Srinivasan Babu, Bennett C. Borer, Travis P. Remarchuk, Robert J. Szendroi, Kathleen R. Whitten, Juliette K. Busse, Kim F. Albizati
  • Methods of making HIV-protease inhibitors and intermediates for making HIV-protease inhibitors
    Patent number: 5925759
    Abstract: HIV protease inhibitors inhibit or block the biological activity of the HIV protease enzyme, causing the replication of the HIV virus to terminate. These compounds can be prepared by the novel methods of the present invention using the novel inventive intermediates.
    Type: Grant
    Filed: September 5, 1997
    Date of Patent: July 20, 1999
    Assignee: Agouron Pharmaceuticals, Inc.
    Inventors: Srinivasan Babu, Bennett C. Borer, Travis P. Remarchuk, Robert J. Szendroi, Kathleen R. Whitten, Juliette K. Busse, Kim F. Albizati
  • Intermediates for making HIV-protease inhibitors
    Patent number: 5705647
    Abstract: HIV protease inhibitors inhibit or block the biological activity of the HIV protease enzyme, causing the replication of the HIV virus to terminate. These compounds can be prepared by the novel methods of the present invention using the novel inventive intermediates.
    Type: Grant
    Filed: September 5, 1996
    Date of Patent: January 6, 1998
    Assignees: Agouron Pharmaceuticals, Inc., Japan Tobacco, Inc.
    Inventors: Srinivasan Babu, Bennett C. Borer, Travis P. Remarchuk, Robert J. Szendroi, Kathleen R. Whitten, Juliette K. Busse, Kim F. Albizati